Unlike mesenchymal markers such as αSMA, fibroblast-specific protein 1 (FSP1), and fibroblast activation protein (FAP) [64], NR2F1 has not been described to be highly expressed in breast cancer CAFs. Here, S100A4 is linked to breast carcinoma.